share_log

Earnings Preview: MediWound

Earnings Preview: MediWound

收益預覽: mediwound
Benzinga ·  00:00

MediWound (NASDAQ:MDWD) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.

納斯達克公司MediWound (NASDAQ:MDWD) 正在準備於2024年11月26日星期二發佈季度業績。投資者在公佈之前應該牢記以下要點。

Analysts expect MediWound to report an earnings per share (EPS) of $-0.44.

分析師預計MediWound的每股收益(EPS)爲-0.44美元。

The announcement from MediWound is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

投資者急切期待MediWound的公告,希望看到超越預期的消息和下個季度的良好指導。

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

值得注意的是,對於新投資者來說,指導可能是股票價格波動的關鍵因素。

Earnings History Snapshot

收益歷史快照

The company's EPS missed by $0.24 in the last quarter, leading to a 4.01% increase in the share price on the following day.

上一季度該公司的每股收益低於0.24美元,導致次日股價上漲4.01%。

Here's a look at MediWound's past performance and the resulting price change:

讓我們來看一下MediWound過去的業績和導致的價格變化:

Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023
EPS Estimate -0.44 -0.41 -0.23 -0.44
EPS Actual -0.68 -0.39 -0.19 -0.24
Price Change % 4.0% 0.0% 0.0% 4.0%
季度 2024年第二季度 2024年第一季度 Q4 2023 Q3 2023
每股收益預估值 -0.44 -0.41 -0.23 -0.44
每股收益實際值 -0.68 -0.39 -0.19 -0.24
價格變更% 4.0% 0.0% 0.0% 4.0%
bigjpg

Performance of MediWound Shares

mediwound股票表現

Shares of MediWound were trading at $16.48 as of November 22. Over the last 52-week period, shares are up 96.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

截至11月22日,MediWound的股價爲16.48美元。在過去的52周內,股價上漲了96.88%。鑑於這些回報通常是正面的,長期股東們應該對即將到來的業績感到滿意。

To track all earnings releases for MediWound visit their earnings calendar on our site.

要追蹤MediWound的所有業績發佈,請訪問我們網站上的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文是由Benzinga的自動內容引擎生成,並由編輯審核。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論